Everand Logo

Welcome to Everand!

  • STAT

    2018 in limericks: The highs and lows from the life sciences

    What a year it's been in the life sciences: CRISPR babies and IPOs galore, high-priced CAR-Ts and gene therapies. We remember it all with the 2018 edition of our year…
    by Meghana Keshavan Dec 28, 2018 1 minute

    It’s been an eventful year in the life sciences, from the struggles of IBM Watson, to China’s twin CRISPR surprise, to a flurry of IPOs, to catching a serial killer with.)

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
    Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About BIO’s China Challenge, Zepbound Shortages, And More
    BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks